Your browser doesn't support javascript.
loading
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
Subbiah, V; Shen, T; Tetzlaff, M; Weissferdt, A; Byers, L A; Cascone, T; Behrang, A; Meric-Bernstam, F; Mooers, B H M; Rothenberg, S M; Ebata, K; Wu, J.
Afiliação
  • Subbiah V; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: vsubbiah@mdanderson.org.
  • Shen T; Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
  • Tetzlaff M; Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Weissferdt A; Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Byers LA; Department of Thoracic-Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Cascone T; Department of Thoracic-Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Behrang A; Division of Radiology, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Mooers BHM; Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, USA; Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
  • Rothenberg SM; Loxo Oncology at Lilly, Stamford, USA.
  • Ebata K; Loxo Oncology at Lilly, Stamford, USA. Electronic address: kevin@loxooncology.com.
  • Wu J; Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, USA. Electronic address: jie-wu@ouhsc.edu.
Ann Oncol ; 32(6): 817-819, 2021 06.
Article em En | MEDLINE | ID: mdl-33617938
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Fusão Oncogênica / Receptor trkC / Proteínas Proto-Oncogênicas c-ret / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas de Fusão Oncogênica / Receptor trkC / Proteínas Proto-Oncogênicas c-ret / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article